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Background: We have uncovered a caspase-dependent (caspase-8/caspase-3/7) signaling governing microglia
activation and associated neurotoxicity. Importantly, a profuse non-nuclear activation of cleaved caspases 8 and 3 was
found in reactive microglia in the ventral mesencephalon from subjects with Parkinson’s disease, thus supporting
the existence of endogenous factors activating microglia through a caspase-dependent mechanism. One obvious
candidate is neuromelanin, which is an efficient proinflammogen in vivo and in vitro and has been shown to have a
role in the pathogenesis of Parkinson’s disease. Consequently, the goal of this study is to test whether synthetic
neuromelanin activates microglia in a caspase-dependent manner.
Results: We found an in-vivo upregulation of CD16/32 (M1 marker) in Iba1-immunolabeled microglia in the ventral
mesencephalon after neuromelanin injection. In vitro experiments using BV2 cells, a microglia-derived cell line,
demonstrated that synthetic neuromelanin induced a significant chemotactic response to BV2 microglial cells,
along with typical morphological features of microglia activation, increased oxidative stress and induction of
pattern-recognition receptors including Toll-like receptor 2, NOD2, and CD14. Analysis of IETDase (caspase-8)
and DEVDase (caspase-3/7) activities in BV2 cells demonstrated a modest but significant increase of both
activities in response to neuromelanin treatment, in the absence of cell death.
Conclusions: Caspase-8 inhibition prevented typical features of microglia activation, including morphological
changes, a high rate of oxidative stress and expression of key proinflammatory cytokines and iNOS.
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Caspases are a family of cysteinyl aspartate-specific pro-
teases that mediate proteolytic events indispensable for
the transduction of signaling pathway controlling bio-
logical phenomena, including apoptosis (programmed
cell death), necrosis, proliferation, differentiation, and in-
flammation [1]. Activation of apoptotic caspases has
been long interpreted as a commitment to cell death [2].
However, recent reports have demonstrated an increased
number of non-apoptotic roles for these caspases [3-6].* Correspondence: jlvenero@us.es
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unless otherwise stated.We recently described a novel and unexpected role for
caspase-8 -3 and -7 in the activation of microglia and as-
sociated neurotoxicity, a finding that could be relevant
in the onset of chronic neurodegenerative diseases [7].
We found that activation of microglial cells with dif-
ferent proinflammogens, including lipopolysaccharide
(a toll-like receptor (TLR) 4 agonist), lipoteichoic acid
(a TLR2 agonist), PamC3sk4 (a TLR 1/2 agonist) and
IFNγ lead to modest but yet significant caspase-3/7
activities in the absence of cell death. Caspase-8 was
found to act as an upstream caspase in this signaling
pathway, since chemical inhibition or gene knockdown
using siRNAs of caspase-8 prevented caspase-3/7 activa-
tion and the subsequent appearance of typical molecular
features of microglia activation [7]. We also analyzed post-ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Viceconte et al. Journal of Neuroinflammation  (2015) 12:5 Page 2 of 15mortem ventral mesencephalon from patients who had
been diagnosed with Parkinson’s disease and found signifi-
cant cytoplasmic expression for active caspase-3 and
caspase-8 in CD68-immunoreactive microglia [7]. This
observation is suggestive of the existence of endogenous
factors capable of activating the microglia through a
caspase-dependent mechanism.
Parkinson’s disease affects approximately 1 to 3% of
the population, and is characterized by a slow and pro-
gressive degeneration of dopaminergic neurons in the
substantia nigra [8]. Accumulating evidence suggests
that inflammation may play a central role in the cell loss
seen in Parkinson’s disease [9,10]. Epidemiological stud-
ies have demonstrated convincingly that the incidence of
idiopathic Parkinson’s disease is lower with chronic use
of anti-inflammatory drugs [11-13]. Evidence of exten-
sive inflammatory response in Parkinson’s disease is well
documented [14]. A number of studies reveal that dam-
aged dopaminergic neurons release several factors that
seem to activate microglia, including neuromelanin, α-
synuclein, and μ-calpain [15,16]. Neuromelanin itself
may induce a neurodegenerative process via an inflam-
matory mechanism, as extracellular neuromelanin has
the ability to activate the central nervous system immune
cells, microglia [17-19]. Released extracellular neuro-
melanin has been observed close to activated microglia cells
in brains from patients with Parkinson’s disease as well as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
parkinsonism [20,21]. The immunological response of
neuromelanin could damage other neurons and lead to a
vicious cycle of neuroinflammation and neurodegeneration
[17,22]. Consequently, we tested the ability of synthetic
neuromelanin to activate BV2 microglia cells through a
caspase-8-dependent mechanism. We found that caspase-8
is involved in the neuromelanin-induced activation of BV2
microglial cells.
Methods
Preparation of synthetic neuromelanin
Dopamine (1.5 g) and cysteine (232 mg) were dissolved
in 1,000 ml of 50 mM phosphate buffer (pH 7.4). The
molar ratio of dopamine to cysteine in this solution is
6:1. The solution of dopamine and cysteine was incu-
bated at 37°C with free air access and vigorous stirring
for 3 days. The resulting black pigment was collected
after centrifugation at 10,000 rpm for 10 min, and
washed with 1% acetic acid and twice with distilled
water. To remove low molecular weight substances, the
resulting synthetic neuromelanin was dialyzed in tubing
with a molecular weight cut off of 12,000 to 14,000
(Sigma-Aldrich, San Luis, MO, USA), which had pre-
viously been treated with EDTA. Finally, the neuro-
melanin was washed twice with distilled water and kept at
4°C until use.Animals and surgery
C57BL/6 mice were obtained from Seville University
(Spain) and had free access to food and water. Experi-
ments were performed in accordance with the Guide-
lines of the European Union Directive 2010/63/EU,
following Spanish regulations for the use of laboratory
animals, and were approved by the Scientific Committee
of the University of Seville.
Intranigral neuromelanin injections (4 μg in 1 μl sterile
saline) were made 1.2 mm posterior, 1.2 mm lateral, and
5.0 mm ventral to the lambda. Two days later, mice were
transcardially perfused under deep anesthesia with 4%
paraformaldehyde and PBS, pH 7.4. Brains were re-
moved, cryoprotected in sucrose and frozen in isopen-
tane at −15°C and serial coronal sections (25 μm thick)
covering the substantia nigra were cut with a cryostat,
mounted on gelatin-coated slides, and further processed
for immunohistochemical analysis of the microglia.
Cell culture
BV2 cells were cultured in DMEM (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% heat-inactivated FBS
(Sigma-Aldrich, San Luis, MO, USA), streptomycin
(100 mg/ml), and penicillin (100 IU/ml) under 100% hu-
midity and 5% CO2. Experiments were performed in re-
duced 5% FBS media.
Cell survival assay
To measure cell viability, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium (MTT) (Sigma-Aldrich, San
Luis, MO, USA) assays were conducted. Briefly, BV2
cells were plated at a density of 1 × 104 cells/ml in 96-
well plates. After incubation for 24 h, the cells were
washed with fresh medium supplemented with 5% FBS
and treated with different concentrations of synthetic
neuromelanin for 12, 24, and 36 h in a humidified incu-
bator. Then 10 μl of MTT solution (2 mg/ml) were
added to each well and cultured for 3 h. After that, the
supernatant was removed and the formazan product
obtained was dissolved in 100 μl dimethylsulfoxide
(Sigma-Aldrich, San Luis, MO, USA). The absorbance
was measured at 570 nm using a microplate reader.
Cell viability in the treated cells is expressed as a per-
centage of the viability of untreated cells.
Assay for total nitrite
The cells were plated on 24-well dishes at a density of
105 cells per well and after 24 h were treated with 1 μg
of neuromelanin for 24 h. The total nitrite content in
the supernatant was measured by incubating superna-
tants with 20 μl of 2,3-diaminonaphtalene solution in
hydrochloric acid and incubating for 10 min at room
temperature, protected from light. The reaction was
stopped by adding 100 μl NaOH, and the total amount
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microplate reader at an excitation wavelength of 363 nm
and an emission wavelength of 426 nm. The nitrite
concentration was calculated using standards prepared
from nitrite standard solution.
Chemotaxis assay
Migration properties of BV2 were evaluated in the pres-
ence and absence of synthetic neuromelanin. The test
was performed using the Chemicon QCM™ Chemotaxis
5 μm 24-well migration assay (Catalog number ECM507,
CHEMICON® International, Millipore), which is based
on the Boyden chamber principle.
The BV2 cells were resuspended in serum-free DMEM
and plated at a concentration of 5 × 105 cells into the
upper compartment of a 24-well transwell plate (5.0 nm
pore size), while to the lower compartment was added
serum-free DMEM plus 0.5 and 1 μg of neuromelanin
and incubated for 21 h at 37°C and 5% CO2. Cells in the
lower chamber were lysed and cell numbers were deter-
mined using CyQUANT® GR dye. The fluorescence
signal was read with a plate reader using a 480/520 nm
filter set. 10% FBS was used as a positive control in the
assay because it is a well-established chemotactic sub-
stance for macrophages and monocytes.
Determination of intracellular reactive oxygen species
content
The intracellular reactive oxygen species (ROS) content,
induced by neuromelanin treatment, was determined in
live cells using the fuorogenic ROS sensor CellROX™
Deep Red Reagent (Invitrogen) at a final concentration
of 5 μM. After 30 min of incubation at 37°C, the
medium was removed, the cells were washed three times
with PBS, and the resulting fluorescence was analyzed
by confocal microscopy (Zeiss LSM 7 Duo).
Determination of apoptotic cell death by propidium
iodide and annexin V-FITC staining
BV2 cells were treated with 1 μg/ml of neuromelanin for
24 h at 37°C. After treatment, cells were washed twice
with cold PBS and resuspended in Binding Buffer (BD
Biosciences, Franklin Lakes, NJ, USA) at a concentration
of 5 × 105 cells/ml in 300 μl. Then BV2 cells were incu-
bated with 5 μl of V500 annexin V (BD Biosciences) for
30 min and with 1 μg/ml of propidium iodide for 1 min
at room temperature in the dark. The reported graph is
representative example of three experiments, which all
gave very similar results.
Caspase 3 and 8 activity assay
Caspase activities were measured using the Caspase-Glo®
kits from Promega (Madison, WI, USA) following the
manufacturer protocol. For that, BV2 cells were seededat a density of 5 × 105/well for 24 h and then treated
with 1 μg/ml of synthetic neuromelanin for 24 h and the
caspase activities measured while the comparing coun-
terpart were first pre-treated with Z-Ile-Glu(OMe)-Thr-
Asp(Ome)-fluoromethylketone (IETD)-fmk for 30 min
and then exposed to neuromelanin.
Real-time PCR
The expression levels of selected gene encoding for
membrane surface receptors (TLR4, TLR2, nucleotide-
binding oligomerization domain-containing protein
(NOD)1, NOD2, receptor for advanced glycation end
products (RAGE), and CD14) and proinflammatory cyto-
kines (such as IL-6, iNOS, IL-1β, and TNF-α) were quanti-
fied using real-time PCR. The BV2 cells were seeded at a
density of 5 × 105 per well for 24 h and then treated with
1 μg/ml of neuromelanin for 6 h and 24 h. Total RNA was
isolated from cells using Rneasy® kit (Qiagen, Hilden,
Germany). cDNA was synthesized from 1 μg of total RNA
using a QuantiTect® reverse transcription kit (Qiagen) in
20 μl reaction volume, as described by the manufacturer.
Real-time PCR was performed using a SensiFAST™ SYBR
No-rox kit (Bioline, London, UK), 0.4 μM primers and
1 μl cDNA. Controls were carried out without cDNA.
Amplification was run in a Mastercycler® ep realplex
(Eppendorf, Hamburg, Germany) thermal cycler at 94°C
for 2 min followed by 35 cycles of 94°C for 30 s, 55 to
60°C for 45 s, and 72°C for 45 s, followed by a final
elongation step at 72°C for 7 min. Following amplifica-
tion, a melting curve analysis was performed by heating
the reactions from 65 to 95°C in 1°C intervals while
monitoring fluorescence. Analysis confirmed a single
PCR product at the predicted melting temperature.
GAPDH served as the reference gene and was used for
sample normalization. The primer sequences used for
amplifications are listed in Table 1.
The relative differences in expression between treated
and untreated cells were determined using cycle time
(Ct) values first normalized with GAPDH of the same
sample and then, the relative differences between control
and treated cells were calculated and expressed as a rela-
tive increases setting control as 100%.
Data were collected and analyzed using the provided
application software. All of the PCR experiments were
performed in triplicate to verify the results.
Flow cytometry analysis
The fluorescent signals were analyzed using an LSRFor-
tessa cytometer (BD Biosciences, Franklin Lakes, NJ,
USA) equipped with a 50 mW 488 nm laser, a 40 mW
640 nm red laser, and a 50 mW 405 nm violet laser. The
fluorescence emissions were detected through a 530/
30 nm band-pass filter for fluorescein isothiocyanate
conjugated antibody (FITC, FL1), a 610/20 nm band-
Table 1 Primers for RT-PCR
Target mRNA Forward (F) and reverse (R) primers
TLR4 F: 5-GGA CTC TGA TCA TGG CAC TG-3
R: 5-CTG ATC CAT GCA TTG GTA GGT-3
TLR2 F: 5-GGG GCT TCA CTT CTC TGC TT-3
R: 5-AGC ATC CTC TGA GAT TTG ACG-3
CD14 F: 5-AAA GAA ACT GAA GCC TTT CTC G-3
NOD1 R: 5-AGC ACC AAG CCA AGC ACA C-3
NOD2 F: 5-AGT GAG GGC GGG AAG TGT-3
R: 5-CCA ATC TGA TTA CCC CAC ATC-3
F: 5-CCC TAG CAC TGA TGC TGG A-3
R: 5-CCC CTT CGT CAC AGA TAT GG-3
RAGE F: 5-GTG TCG GGC AAC TAA CAG G-3
R: 5-CTG GCT TCC CAG GAA TCT G-3
IL-6 F: 5-TTC TTG GGA CTG ATG CTG-3
R: 5-CTG GCT TTG TCT TTC TTG TT-3
IL-1β F: 5-TTG ACG GAC CCC AAA AGA TG-3
R: 5-AGA AGG TGC TCA TGT CCT CA-3
iNOS F: 5-CTT TGC CAC GGA CGA GAC-3
R: 5-TCA TTG TAC TCT GAG GGC TGA C-3
TNF-α F: 5-AGC CCA CGT AGC AAA CCA CC-3
R: 5-AAC ACC CAT TCC CTT CAC AGA GC-3
GPDH F: 5-AAC GAC CCC TTC ATT GAC C-3
R: 5-TCA GAT GCC TGC TTC ACC-3
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band-pass filter for allophycocyanin (FL12). At least
10,000 events per sample were acquired in log mode.
Percentages of cells were calculated using fluorescence-
activated cell sorting and Diva Software (BD Biosciences,
Franklin Lakes, NJ, USA).
Fluorescence immunohistochemistry
Thaw-mounted 20-μm coronal sections were cut on a
cryostat at −15°C and mounted in gelatin-coated slides.
For double-labeling of Iba-1 with CD16/CD32 (CD16/
32), sections were blocked with PBS containing 1%
normal goat serum and chicken serum (Vector Labora-
tories, Burlingame, CA, USA) for 1 h. The slides were
washed three times in PBS and then incubated overnight
at 4°C with either rabbit-derived anti-Iba-1 (1:300;
Wako) or rat-derived anti-CD16/32 (1:500; BD Bio-
sciences) diluted in PBS containing 1% normal goat or
chicken serum and 0.25% Triton X-100. Sections were
incubated with goat anti-rabbit secondary antibody con-
jugated to fluorescein (1:200, for Iba1; Vector) and
chicken anti-rat secondary antibody conjugated to Alexa
Fluor® 594 (1: 200, for CD16/32; Invitrogen) for 1 h at
22 ± 1°C in the dark. This addition was preceded by
three 10-min rinses in PBS. As a control, another set ofsections was incubated with only the Iba-1 antibody and
then visualized using both filters. No signal was detected
when Iba-1 alone with fluorescein filter was used
(photomicrograph not shown). The same was true with
CD16/32 when Alexa Fluor® 594 filter was used. Fluores-
cence images were acquired using a confocal laser scan-
ning microscope (Zeiss LSM 7 DUO) and processed
using its associated software package (ZEN 2010).Statistical analysis
All data were collected from three or more independent
experiments and values were expressed as means ±
standard deviation. Statistical analysis was performed
using Student’s t test and one-way analysis of variance
(ANOVA). Values of P less than 0.05 were considered
statistically significant.Results
Effect of intranigral injection of neuromelanin on
microglia population
We first tested the effect of intranigral neuromelanin
injections on microglia population in terms of Iba1
(general microglia marker) and CD16/32 (specific M1
proinflammatory marker). In sham-injected animals, the
microglia were mostly quiescent, characterized by small
cell bodies, fine cytoplasmic ramifications, and low to
moderate Iba1 expression (Figure 1). CD16/32 expres-
sion was very low, supporting the quiescent nature of
microglia in sham-injected animals. In contrast, neuro-
melanin injection strongly activated microglia; that is,
cells showing thickening of processes and increased cell
body size and Iba1 expression (Figure 1). Moreover,
there was a strong induction of CD16/32 expression
within Iba1-expressing microglial cells, thus supporting
a proinflammatory phenotype (Figure 1).Effects of synthetic neuromelanin on BV2 cells viability
A dose-response study of cell viability (MTT assay) after
neuromelanin treatment was performed at three time
points (12, 24, and 36 h) to establish the optimal con-
centration of synthetic neuromelanin to be used in the
following studies on microglia activation. Neuromelanin
was used in a range from 50 ng to 50 μg. Even the high-
est dose tested (50 μg) failed to decrease cell survival at
12 h (Figure 2), but produced a significant decrease at
24 h (86.3% of control value). At 36 h, a significant
decrease in viability was found from 500 ng onward. We
selected a dose of 1 μg/ml of neuromelanin, since it was
able to activate microglia cells at short times (12 to
24 h) without inducing cell death, as confirmed by flow
cytometry analysis with annexin V and propidium iodide
(Figure 3).
Figure 1 Effect of in-vivo intranigral injection of neuromelanin on microglia population. Microglia population was evaluated in terms of Iba1
(A,D) and CD16/32 (B,E) in sham (A-C) and neuromelanin-injected animals (D-F). Inserts in C and F are high-magnification photographs of each
condition. Note the typical morphological features of activated microglia in response to neuromelanin injections in terms of Iba1 (D) and upregulation
of CD16/32 (E). The dashed line in D-F shows the presence of insoluble neuromelanin within the ventral mesencephalon. Scale bar, 100 μm.
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Microglia are migratory cells that accumulate in vivo at
sites of tissue injury. This property is important for
many pathophysiological processes, including immune
defense and wound healing. The effect of neuromelaninNeur
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Figure 3 Flow-cytometric analysis of BV2 cell viability. Cells were analyzed using propidium iodide and annexin V. (A) Control cells. (B)
Staurosporine (1 μM for 12 h, as death control). (C) BV2 cells + 1 μg/ml of neuromelanin for 24 h. (D) Quantification of cell survival. Results are
mean ± standard deviation of three independent experiments, and are expressed as percentage of control values. Statistical analysis was made
using Student’s t test. *, P < 0.01 compared with control values. Cont., control; NM, neuromelanin; PI, propidium iodide; STS, staurosporine.
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2 μg of synthetic neuromelanin, respectively, compared
with vehicle (Figure 4).
Activation of nitric oxide production by neuromelanin
Features of microglial activation are the production of
nitric oxide, ROS, and proinflammatory factors. Conse-
quently, microglia activation was first evaluated in terms
of released nitrite upon neuromelanin treatment. Total
nitrite levels were measured in the supernatant obtained
from BV2 cells incubated with 1 μg/ml of synthetic
neuromelanin. A significant increase of 42.4% of nitrite
production was detected after 24 h of neuromelaninexposure, as compared with control cells (P < 0.01,
Figure 5). For comparative purposes, we also analyzed
nitrite levels after treating BV2 cells for 24 h with
1 μg/ml lipopolysaccharide (125.0% increase, P < 0.01
compared with control levels).
Expression of pattern-recognition receptors in response
to synthetic neuromelanin
Activation of microglial cells largely relies upon binding
to and stimulation of pattern-recognition receptors,
thus leading to a high transcriptional response, includ-
ing the receptors themselves. We used RT-PCR to
quantify the mRNA levels encoding for key surface
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Figure 4 Chemotaxis of BV2 cells induced by synthetic neuromelanin. Results are mean ± standard deviation of three independent
experiments, and are expressed as relative fluorescent units. Statistical analysis: one-way ANOVA followed by the least significant difference
post-hoc test for multiple comparisons. α = 0.05 was used. F (3,11) = 45.35, P = 0.0000. All treatments are statistically different from each other.
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and NOD1 and NOD2. BV2 cells were seeded at a density
of 5 × 105 cells per well for 24 h and then treated with
1 μg/ml of neuromelanin for 12 h and 24 h. For compara-
tive purposes, we also quantified the different mRNAs in
response to lipopolysaccharide.
Neuromelanin induced a significant increase (P < 0.01)
in the mRNA expression of TLR2 (298.4% of control
value) and NOD2 receptors (305.8% of control value) at
12 h (Figure 6A), which then slightly decreased at 24 h
(211.0% and 252.1% of control value for TLR2 and
NOD2, respectively; P < 0.01 with respect to controlControl LPS NM
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Figure 5 Activation of nitric oxide production by neuromelanin.
Results are mean ± standard deviation of three independent
experiments, and are expressed as pmol of nitrite. Statistical analysis:
one-way ANOVA followed by the least significant difference post-hoc
test for multiple comparisons. α = 0.05 was used. F (2,8) = 168.02,
P < 0.01. All treatments are statistically different from each other.value), when we observed a high induction of CD14 gene
mRNA expression (272.8% of control value, P < 0.01;
Figure 6B).
Analysis of caspase-3 and -8 activities in response to syn-
thetic neuromelanin
Caspases -3 and -8 are well known members of the kill-
ing caspases, but they also have non-apoptotic roles. It
has been recently demonstrated that their moderate
activation is involved in the activation of microglia in re-
sponse to different proinflammogens. Consequently,
caspase-3 and -8 activities were assessed using a
Caspase-Glo® assay (Promega) in response to neuro-
melanin and in the presence or absence of IETD-fmk,
an inhibitor of caspase-8 activity, added to the culture 24 h
before neuromelanin or lipopolysaccharide (Figure 7).
Neuromelanin induced a modest but still significant in-
crease in the activity of caspase-3 (138.1% of control values,
P < 0.05) and caspase-8 (120.9% of control value, P < 0.01;
Figure 7). IETD-fmk reduced both lipopolysaccharide- and
neuromelanin-induced caspase-3 and -8 activities.
Neuromelanin induces release of proinflammatory factors
We used RT-PCR to examine the level of expression of
different cytokine genes in microglial cell cultures after
6 h and 24 h of treatment with neuromelanin and in the
presence and absence of IETD-fmk. After stimulation of
BV2 cells with neuromelanin, PCR analysis revealed an
increased and time-dependent effect of neuromelanin on
the mRNA levels for TNF-α, IL-1β, IL-6, and iNOS gene
expression. After 6 h of exposure, an increase in TNF-α,
IL-1β, and IL-6 gene expression was evident (Figure 8);
at 24 h, an increase of iNOS expression was also evident
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Figure 6 Expression of pattern-recognition receptors in response to synthetic neuromelanin. mRNA levels were quantified using real-time
RT-PCR. BV2 cells were cultured for 24 h and then treated with 1 μg/ml of neuromelanin for 12 h and (B) 24 h. Results are mean ± standard
deviation of three independent experiments, and are expressed as percentage of control values. Statistical analysis was made using Student’s t
test. *, P < 0.01 compared with control values. LPS, lipopolysaccharide; NM, neuromelanin.
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preceded by a 24 h treatment with IETD-fmk, a reduc-
tion of gene expression was observed, demonstrating a
direct involvement of caspase-8 in proinflammatory fac-
tor induction in the presence of proinflammatory stimuli
(Figures 8 and 9).
ROS generation in response to synthetic neuromelanin
Microglia are known to produce ROS upon activation.
Intracellular ROS generation was observed in BV2 cells
after a 24 h exposure to neuromelanin (Figure 10).
CellROX®, a fluorogenic probe that exhibits fluorescence
upon oxidation by ROS, was used. The intensity of
the fluorescent signal, reflecting the amount of ROSgeneration, showed significant increases in reactive oxygen
species in cells treated with neuromelanin and lipopoly-
saccharide (Figure 10). Significantly less ROS generation
was observed when BV2 cells were first pre-treated for
24 h with IETD-fmk, a selective caspase-8 inhibitor, and
then exposed to lipopolysaccharide or neuromelanin.
IETD-fmk inhibits the activation of microglia induced by
neuromelanin
A clear chemoattraction and morphological change typ-
ical of activation is evident in BV2 cells in response to
neuromelanin treatment. Caspase-8 inhibition by IETD-
fmk clearly prevented neuromelanin-induced morpho-
logical changes associated with microglia activation
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Figure 7 Neuromelanin-induced caspase-3 and -8 activities. Caspase 3 and 8 activities were assessed using the Caspase-Glo® Assay (Promega).
Results are mean ± standard deviation of at least three independent experiments, and are expressed as percentage of control values. Statistical analysis:
one-way ANOVA followed by the least significant difference post-hoc test for multiple comparisons. α = 0.05 was used. *, P < 0.05; **, P < 0.01 compared
with the control group; a, compared with the same treatment without the inhibitor IETD-fmk, P < 0.01. Cont., control; LPS, lipopolysaccharide; LPS + I,
lipopolysaccharide plus IETD-fmk; NM, neuromelanin; NM+ I, neuromelanin plus IETD-fmk.
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achieve this, cells were exposed to IETD-fmk for 24 h
and then to neuromelanin for an additional 24 h. The
effect of lipopolysaccharide was also tested, for com-
parative purposes.
Discussion
We have previously reported an unexpected non-
apoptotic role of caspases in the control of microglia ac-
tivation and associated neurotoxicity [7]. We found that
stimulation of microglia with various inflammogens acti-
vates caspase-8 and caspase-3/7 in the absence of cell
death in vitro and in vivo. Knockdown or chemical
inhibition of either one, or both, of these caspases
hindered microglia activation and, importantly, reduced
neurotoxicity. We also observed that these caspases are
activated in microglia in the ventral mesencephalon in
subjects with Parkinson’s disease. The question that
arises deals with the potential endogenous inflammogens
capable of activating microglia by a caspase-dependent
mechanism.
Since the first indications for an active immune system
in the ventral mesencephalon of patients with Parkin-
son’s disease (the presence of cytotoxic T lymphocytes
and reactive microglia) were reported [23,24], numerous
studies have suggested a prominent role of brain inflam-
mation in the etiopathology of Parkinson’s disease
[25-27]. Studies on brains from human beings [28] who
had self-administered MPTP, and monkeys [29] receiving
the same toxin, besides showing a striking microglial activa-
tion, showed a significant accumulation of extraneuronalneuromelanin, a clear indication that neuromelanin might
have an active role in activating microglia in the parkinson-
ian brain. Supporting this, neuromelanin has been demon-
strated surrounded by, or within, activated microglia in the
parkinsonian brain post-mortem [30], and the number of
activated microglia in the aging substantia nigra is signifi-
cantly and positively correlated with the amount of extra-
cellular neuromelanin. [31]. Furthermore, neuromelanin
has been shown to stimulate neuroinflammation and cell
loss when injected into the substantia nigra of the rat [18].
Interestingly, Double et al. [32] have demonstrated that sera
from subjects with clinical Parkinson’s disease display a sig-
nificantly enhanced IgG response to melanins derived from
catecholamines. This finding is suggestive of a specific
humoral immune response stimulated by the release of
neuromelanin from dying dopaminergic neurons into the
extraneuronal space and its subsequent removal from the
brain by microglia [33-35]. The main precursor to neuro-
melanin is dopamine and cysteine appears to be partially
incorporated [22]. With these precedents, we used a syn-
thetic melanin from dopamine and cysteine. Because of the
limited availability of neuromelanin [36], it is very import-
ant to develop a good model for producing synthetic neuro-
melanin that allows systematic studies aimed at elucidating,
for instance, molecular pathways triggering brain inflam-
mation. With this consideration, Zecca and colleagues de-
veloped a method for producing neuromelanin from
autoxidation of dopamine in the presence of cysteine [37].
We first tested the ability of synthetic neuromelanin to
activate microglia in vivo. Thus, we injected neuromela-
nin in the ventral mesencephalon and analyzed the
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(See figure on previous page.)
Figure 8 Induction of proinflammatory factors after 6 h of exposure to neuromelanin. mRNA expression was quantified by real-time
RT-PCR 6 hours after the start of the experiments. (A) TNF-α. (B) IL-1β. (C) IL-6. Results are mean ± standard deviation of three independent
experiments, and are expressed as percentage of control values. Statistical analysis: one-way ANOVA followed by the least significant difference
post-hoc test for multiple comparisons. α = 0.05 was used. *, compared with control value, P < 0.01; a, compared with the same treatment without
the inhibitor IETD-fmk, P < 0.01. LPS, lipopolysaccharide; NM, neuromelanin.
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glia. Even though we found morphological changes
typically associated with microglia activation, we also
performed double Iba1-CD16/32 immunohistochemical
analysis. CD16/32, when expressed in microglia, is a
phenotypic marker of M1 polarization [38,39]. We found
a clear upregulation of CD16/32 in Iba1-immunolabeled
microglia, consistent with the microglia activating effect
of synthetic neuromelanin. Next, we set up a cell culture
system to test the ability of synthetic neuromelanin to
activate microglia and the potential role of caspase-8 in
neuromelanin-induced microglia activation. For that, we
took advantage of BV2 cells, which we have successfully
used in the context of caspase-8/3/7-dependent microglia0
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Figure 9 Induction of proinflammatory factors after 24 h of exposure
RT-PCR 24 h after the start of the experiments. (A) TNF-α. (B) IL-1β. (C) IL-6
experiments, and are expressed as percentage of control values. Statistical
post-hoc test for multiple comparisons. α = 0.05 was used. *, compared wit
the inhibitor IETD-fmk, P < 0.01. LPS, lipopolysaccharide; NM, neuromelanin.activation in response to classical inflammogens including
lipopolysaccharide and IFNγ [7]. Since caspases are critic-
ally involved in apoptotic cell death, we first analyzed the
effect of increasing doses of neuromelanin in cell survival
and apoptosis. Doses of up to 50 μg neuromelanin did not
compromise BV2 cell survival. The neuromelanin dose se-
lected for most of these studies (1 μg) failed to induce
apoptosis as demonstrated by annexin V and propidium
iodide fluorescence-activated cell sorting. We next tested
the ability of 1 μg neuromelanin to induce microglia acti-
vation. To achieve this, we demonstrated (i) a positive
chemotaxis assay, (ii) an increase of nitrite levels, a stable
breakdown product of nitric oxide [40], and (iii) significant
upregulation of cytokine mRNAs, including IL-1β, TNF-α,0
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to neuromelanin. mRNA expression was quantified by real-time
. (D) iNOS. Results are mean ± standard deviation of three independent
analysis: one-way ANOVA followed by the least significant difference
h control value, P < 0.01; a, compared with the same treatment without
Figure 10 Production of ROS induced by neuromelanin. The fluorogenic probe CellROX® becomes fluorescent upon oxidation by ROS. (A)
Control. (B) Control + IETD-fmk. (C) Neuromelanin 1 μg. (D) Neuromelanin 1 μg + IETD-fmk. (E) Lipopolysaccharide 1 μg. (F) Lipopolysaccharide
1 μg + IETD-fmk. (G) Quantification of ROS production. Results are mean ± standard deviation of three independent experiments, and are
expressed as a percentage of control values. Statistical analysis: one-way ANOVA followed by the least significant difference post-hoc test for
multiple comparisons. α = 0.05 was used. *, compared with control value, P < 0.01; a, compared with the same treatment without the inhibitor
IETD-fmk, P < 0.01. Scale bar, 50 μm. Cont., control; LPS, lipopolysaccharide; NM, neuromelanin; ROS, reactive oxygen species.
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Figure 11 IETD-fmk inhibits microglial activation induced by neuromelanin. Phase contrast micrograph of BV2 cultures under different
treatments. (A) Control cells, showing the round morphology characterizing resting microglial cells in culture. (B) The caspase-8 inhibitor IETD-fmk
showed no effect on resting cells. (C) Lipopolysaccharide, used as a positive control, induced clear changes in the cells morphology (white arrowheads),
which lost their resting round shape. (D) IETD-fmk reduced the activation induced by lipopolysaccharide in the BV2 cells. (E) Neuromelanin (black
deposits marked by black arrows) induced a clear activation of BV2 cells, in a similar way to the proinflammogen lipopolysaccharide. (F) Inhibition
of caspase-8 prevented the activation of BV2 cells induced by neuromelanin. Round resting cells in close contact with neuromelanin can be seen
(white arrows). Scale bar, 50 μm. LPS, lipopolysaccharide; NM, neuromelanin.
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expression of pattern-recognition receptors is increased in
microglia [15]. More importantly, expression levels for
TLR2, TLR5, and CD14 are increased in Parkinson’s dis-
ease [15,41,42]. Consequently, we extended our study to
key pattern-recognition receptors, including TLR2, TLR4,
CD14, RAGE, NOD1, and NOD2. For comparative pur-
poses, we also studied the effect of lipopolysaccharide.
Interestingly, both neuromelanin and lipopolysaccharide
rendered quite similar results, including upregulation ofTLR2, CD14, and NOD2 but not TLR4. Taken together,
our results demonstrate that synthetic neuromelanin is a
potent proinflammogen in vivo and in vitro, even mimick-
ing key molecular events associated with a classical inflam-
matory response, like that induced by lipopolysaccharide.
However, in contrast with lipopolysaccharide, neuro-
melanin should be considered a clear inducer of sterile
inflammation (that occurring in the absence of any
microorganism), which is supposed to play critical
roles in neurodegenerative diseases.
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killing caspases are associated with certain cellular com-
partments (that is, nuclear versus cytoplasmic), along
with a restricted timing and intensity of signal pathway
activation [7,15,43]. In agreement, we demonstrated a
moderated yet significant increase of caspase-8 and
caspase-3 in BV2 microglia in response to classical
proinflammogens, including lipopolysaccharide (TLR4
agonist), lipoteichoic acid (TLR2 agonist), PamC3sk4
(synthetic lipopeptide TLR1/2 agonist), and IFNγ, in
contrast with a death stimulus induced by staurospor-
ine, which led to significantly greater caspase activity
[7]. Consequently, we measured DEVDase (caspase-3/7)
and IETDase (caspase-8) activities in response to neuro-
melanin. Our data demonstrate that, concomitant with
microglia activation, both activities were moderately yet
significant increased after neuromelanin treatment. As
stated before, even the highest neuromelanin doses tested
failed to induce significant cell death, a prerequisite to ex-
clude the neuromelanin-induced IETDase and DEVDase
activities in triggering cell death. Consequently, we next
tested the ability of IETD-fmk, a specific caspase-8 inhibi-
tor, to counteract neuromelanin-induced proinflammatory
microglia activation. Oxidative stress generated by reactive
microglia is supposed to be the most critical factor in
inducing the death of neuronal populations [44], and it is
highly relevant for the pathogenesis of Parkinson’s disease,
as nigral dopamine neurons are highly vulnerable to
oxidative stress [8]. Consequently, we used a fluorogenic
probe to measure cellular oxidative stress in response to
neuromelanin in the presence and absence of IETD-fmk, a
specific caspase-8 inhibitor. From these experiments, it
was clear that (i) BV2 cells showed a clear positive chemo-
taxis and moved towards areas with insoluble neuro-
melanin, (ii) neuromelanin induced morphological
changes typical of microglia activation; (iii) neuromelanin-
treated cells strongly increased oxidative stress, and (iv)
caspase-8 inhibition prevented typical morphological fea-
tures of microglia activation and associated oxidative
stress. In keeping with this view, activated microglia upre-
gulates different enzymes involved in the inflammatory
processes mediated by oxidative stress, including iNOS,
NADPH oxidase, COX-2, and myeloperoxidase [15].
Moreover, stimulated microglia upregulate a wide variety
of proinflammatory mediators including cytokines. All
these events related to microglia activation potentially
contribute to neuronal dysfunction and death. Conse-
quently, and to further confirm that caspase-8 inhibition
prevents neuromelanin-induced microglia activation, we
measured main proinflammatory cytokines including IL-
1β, IL-6, TNF-α, and expression of iNOS. Our results
demonstrated that caspase-8 inhibition partially but sig-
nificantly prevented neuromelanin-induced upregulation
of the mentioned cytokines and iNOS. Taken together, ourresults demonstrate a caspase-dependent activation of
microglia in response to synthetic neuromelanin.
Conclusions
We demonstrated that synthetic neuromelanin is an effi-
cient proinflammogen in vivo and in vitro. Neuromelanin
also exhibited a very significant chemotactic response to
BV2 microglial cells. Analysis of IETDase and DEVDase
activities in BV2 cells demonstrated a modest yet signifi-
cant increases of caspase-8 and caspase-3 activities in
response to neuromelanin treatment. A dose-response
study demonstrated the ability of neuromelanin to activate
microglia in the absence of cell death. Consequently,
the neuromelanin-induced activation of caspase-8 and
caspase-3/7 are suggestive of non-apoptotic roles of these
killing caspases. Supporting this, caspase-8 inhibition pre-
vented typical features of microglial activation, including
morphological changes, a high rate of oxidative stress and
expression of key proinflammatory cytokines and iNOS.
Neuromelanin released by damaged dopaminergic neurons
is suspected to play a major role in brain inflammation as-
sociated with Parkinson’s disease. Elucidating molecular
mechanisms associated with neuromelanin-induced micro-
glia activation are crucial for establishment of future
pharmacological strategies aimed at preventing microglia
neurotoxicity. Our data demonstrate a key role of caspase-8
in microglia activation induced by neuromelanin.
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